Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells

Authors: Kun Pang, Zhiguo Zhang, Lin Hao, Zhenduo Shi, Bo Chen, Guanghui Zang, Yang Dong, Rui Li, Ying Liu, Jie Wang, Jianjun Zhang, Longjun Cai, Xiaoxiao Han, Conghui Han

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

This study aimed to determine whether the enhancer of the rudimentary homolog (ERH) gene regulates cell migration and invasion in human bladder urothelial carcinoma (BUC) T24 cells and the underlying mechanism.

Methods

First, we knocked down ERH in BUC T24 and 5637 cells by shRNA and then used wound healing cell scratch migration assays, transwell cell migration assays, transwell cell invasion chamber experiments and nude mouse tail vein transfer assays to determine the migration and invasion ability after ERH was knocked down. Moreover, we used gene expression profiling chip analysis and further functional experiments to explore the possible mechanism through which ERH knockdown downregulated metastasis ability in T24 cells.

Results

Wound healing cell scratch migration assays, transwell cell migration assays, transwell cell invasion chamber experiments and nude mouse tail vein transfer assays all showed that the metastasis ability was significantly inhibited in human BUC T24 and 5637 cells with ERH knockdown. A gene expression profiling chip analysis in T24 cells showed that the MYC gene may be an important downstream target of the ERH gene, and the functional experiments showed that MYC is a functional target of ERH in BUC T24 cells.

Conclusion

ERH knockdown could inhibit the metastasis of BUC T24 cells in vitro and in vivo. This study further explored the mechanism of the ERH gene in the metastasis of the T24 human bladder cancer cell line and found that ERH may regulate MYC gene expression. The results of this research provide a basis for the clinical application of ERH as a potential target for BUC treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRef
2.
go back to reference Zheng L, Chen K, Zhu L, Su D, Cheng G. Low expression of DAB2IP predicts an unfavorable prognosis in human bladder carcinoma. OncoTargets and therapy. 2017;10:5719–26.CrossRef Zheng L, Chen K, Zhu L, Su D, Cheng G. Low expression of DAB2IP predicts an unfavorable prognosis in human bladder carcinoma. OncoTargets and therapy. 2017;10:5719–26.CrossRef
3.
go back to reference Dettlaff K, Stawny M, Ogrodowczyk M, Jelinska A, Bednarski W, Watrobska-Swietlikowska D, Keck RW, Khan OA, Mostafa IH, Jankun J. Formulation and characterization of EGCG for the treatment of superficial bladder cancer. Int J Mol Med. 2017;40(2):329–36.CrossRef Dettlaff K, Stawny M, Ogrodowczyk M, Jelinska A, Bednarski W, Watrobska-Swietlikowska D, Keck RW, Khan OA, Mostafa IH, Jankun J. Formulation and characterization of EGCG for the treatment of superficial bladder cancer. Int J Mol Med. 2017;40(2):329–36.CrossRef
4.
go back to reference Gelsthorpe M, Pulumati M, McCallum C, Dang-Vu K, Tsubota SI. The putative cell cycle gene, enhancer of rudimentary, encodes a highly conserved protein found in plants and animals. Gene. 1997;186(2):189–95.CrossRef Gelsthorpe M, Pulumati M, McCallum C, Dang-Vu K, Tsubota SI. The putative cell cycle gene, enhancer of rudimentary, encodes a highly conserved protein found in plants and animals. Gene. 1997;186(2):189–95.CrossRef
5.
go back to reference Pang K, Lv Q, Ning SY, Hao L, Shi ZD, Zang GH, Shen K, Zhu XY, Zhu GY, Wang X, et al. ERH is up-regulated in bladder cancer and regulates the proliferation and apoptosis of T24 bladder cancer cells. Int J Clin Exp Med. 2017;10(11):15269–77. Pang K, Lv Q, Ning SY, Hao L, Shi ZD, Zang GH, Shen K, Zhu XY, Zhu GY, Wang X, et al. ERH is up-regulated in bladder cancer and regulates the proliferation and apoptosis of T24 bladder cancer cells. Int J Clin Exp Med. 2017;10(11):15269–77.
6.
go back to reference Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN, Shirley Liu X, Struhl K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell. 2010;17(4):348–61.CrossRef Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN, Shirley Liu X, Struhl K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell. 2010;17(4):348–61.CrossRef
7.
go back to reference Arai R, Kukimoto-Niino M, Uda-Tochio H, Morita S, Uchikubo-Kamo T, Akasaka R, Etou Y, Hayashizaki Y, Kigawa T, Terada T, et al. Crystal structure of an enhancer of rudimentary homolog (ERH) at 2.1 angstroms resolution. Protein science : a publication of the Protein Society. 2005;14(7):1888–93.CrossRef Arai R, Kukimoto-Niino M, Uda-Tochio H, Morita S, Uchikubo-Kamo T, Akasaka R, Etou Y, Hayashizaki Y, Kigawa T, Terada T, et al. Crystal structure of an enhancer of rudimentary homolog (ERH) at 2.1 angstroms resolution. Protein science : a publication of the Protein Society. 2005;14(7):1888–93.CrossRef
8.
go back to reference Wan C, Tempel W, Liu ZJ, Wang BC, Rose RB. Structure of the conserved transcriptional repressor enhancer of rudimentary homolog. Biochemistry. 2005;44(13):5017–23.CrossRef Wan C, Tempel W, Liu ZJ, Wang BC, Rose RB. Structure of the conserved transcriptional repressor enhancer of rudimentary homolog. Biochemistry. 2005;44(13):5017–23.CrossRef
9.
go back to reference Jin T, Guo F, Serebriiskii IG, Howard A, Zhang YZ. A 1.55 a resolution X-ray crystal structure of HEF2/ERH and insights into its transcriptional and cell-cycle interaction networks. Proteins. 2007;68(2):427–37.CrossRef Jin T, Guo F, Serebriiskii IG, Howard A, Zhang YZ. A 1.55 a resolution X-ray crystal structure of HEF2/ERH and insights into its transcriptional and cell-cycle interaction networks. Proteins. 2007;68(2):427–37.CrossRef
10.
go back to reference Pogge von Strandmann E, Senkel S, Ryffel GU. ERH (enhancer of rudimentary homologue), a conserved factor identical between frog and human, is a transcriptional repressor. Biol Chem. 2001;382(9):1379–85.PubMed Pogge von Strandmann E, Senkel S, Ryffel GU. ERH (enhancer of rudimentary homologue), a conserved factor identical between frog and human, is a transcriptional repressor. Biol Chem. 2001;382(9):1379–85.PubMed
11.
go back to reference Zafrakas M, Losen I, Knuchel R, Dahl E. Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue. BMC Cancer. 2008;8:145.CrossRef Zafrakas M, Losen I, Knuchel R, Dahl E. Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue. BMC Cancer. 2008;8:145.CrossRef
12.
go back to reference Lukasik A, Uniewicz KA, Kulis M, Kozlowski P. Ciz1, a p21 cip1/Waf1-interacting zinc finger protein and DNA replication factor, is a novel molecular partner for human enhancer of rudimentary homolog. FEBS J. 2008;275(2):332–40.CrossRef Lukasik A, Uniewicz KA, Kulis M, Kozlowski P. Ciz1, a p21 cip1/Waf1-interacting zinc finger protein and DNA replication factor, is a novel molecular partner for human enhancer of rudimentary homolog. FEBS J. 2008;275(2):332–40.CrossRef
13.
go back to reference Richardson CJ, Broenstrup M, Fingar DC, Julich K, Ballif BA, Gygi S, Blenis J. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol. 2004;14(17):1540–9.CrossRef Richardson CJ, Broenstrup M, Fingar DC, Julich K, Ballif BA, Gygi S, Blenis J. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol. 2004;14(17):1540–9.CrossRef
14.
go back to reference Onyango P, Feinberg AP. A nucleolar protein, H19 opposite tumor suppressor (HOTS), is a tumor growth inhibitor encoded by a human imprinted H19 antisense transcript. Proc Natl Acad Sci U S A. 2011;108(40):16759–64.CrossRef Onyango P, Feinberg AP. A nucleolar protein, H19 opposite tumor suppressor (HOTS), is a tumor growth inhibitor encoded by a human imprinted H19 antisense transcript. Proc Natl Acad Sci U S A. 2011;108(40):16759–64.CrossRef
15.
go back to reference Weng MT, Luo J. The enigmatic ERH protein: its role in cell cycle, RNA splicing and cancer. Protein & cell. 2013;4(11):807–12.CrossRef Weng MT, Luo J. The enigmatic ERH protein: its role in cell cycle, RNA splicing and cancer. Protein & cell. 2013;4(11):807–12.CrossRef
16.
go back to reference Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, et al. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A. 2012;109(52):E3659–67.CrossRef Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, et al. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A. 2012;109(52):E3659–67.CrossRef
17.
go back to reference Ishikawa K, Ishikawa A, Shoji Y, Imai T. A genotoxic stress-responsive miRNA, miR-574-3p, delays cell growth by suppressing the enhancer of rudimentary homolog gene in vitro. Int J Mol Sci. 2014;15(2):2971–90.CrossRef Ishikawa K, Ishikawa A, Shoji Y, Imai T. A genotoxic stress-responsive miRNA, miR-574-3p, delays cell growth by suppressing the enhancer of rudimentary homolog gene in vitro. Int J Mol Sci. 2014;15(2):2971–90.CrossRef
18.
go back to reference Weng MT, Tung TH, Lee JH, Wei SC, Lin HL, Huang YJ, Wong JM, Luo J, Sheu JC. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. Sci Rep. 2015;5:9357.CrossRef Weng MT, Tung TH, Lee JH, Wei SC, Lin HL, Huang YJ, Wong JM, Luo J, Sheu JC. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. Sci Rep. 2015;5:9357.CrossRef
19.
go back to reference Zeng T, Peng L, Chao C, Fu B, Wang G, Wang Y, Zhu X. miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT. Int J Clin Exp Pathol. 2014;7(11):7653–62.PubMedPubMedCentral Zeng T, Peng L, Chao C, Fu B, Wang G, Wang Y, Zhu X. miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT. Int J Clin Exp Pathol. 2014;7(11):7653–62.PubMedPubMedCentral
20.
go back to reference Ko H, Jeon H, Lee D, Choi HK, Kang KS, Choi KC. Sanguiin H6 suppresses TGF-beta induction of the epithelial-mesenchymal transition and inhibits migration and invasion in A549 lung cancer. Bioorg Med Chem Lett. 2015;25(23):5508–13.CrossRef Ko H, Jeon H, Lee D, Choi HK, Kang KS, Choi KC. Sanguiin H6 suppresses TGF-beta induction of the epithelial-mesenchymal transition and inhibits migration and invasion in A549 lung cancer. Bioorg Med Chem Lett. 2015;25(23):5508–13.CrossRef
21.
go back to reference Tang J, Li Y, Wang J, Wen Z, Lai M, Zhang H. Molecular mechanisms of microRNAs in regulating epithelial-mesenchymal transitions in human cancers. Cancer Lett. 2016;371(2):301–13.CrossRef Tang J, Li Y, Wang J, Wen Z, Lai M, Zhang H. Molecular mechanisms of microRNAs in regulating epithelial-mesenchymal transitions in human cancers. Cancer Lett. 2016;371(2):301–13.CrossRef
22.
go back to reference Zhao J, Dong D, Sun L, Zhang G, Sun L. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer. International braz j urol : official journal of the Brazilian Society of Urology. 2014;40(2):179–89.CrossRef Zhao J, Dong D, Sun L, Zhang G, Sun L. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer. International braz j urol : official journal of the Brazilian Society of Urology. 2014;40(2):179–89.CrossRef
23.
go back to reference Hong D, Park MJ, Jang EH, Jung B, Kim NJ, Kim JH. Hispolon as an inhibitor of TGF-beta-induced epithelial-mesenchymal transition in human epithelial cancer cells by co-regulation of TGF-beta-snail/twist axis. Oncol Lett. 2017;14(4):4866–72.CrossRef Hong D, Park MJ, Jang EH, Jung B, Kim NJ, Kim JH. Hispolon as an inhibitor of TGF-beta-induced epithelial-mesenchymal transition in human epithelial cancer cells by co-regulation of TGF-beta-snail/twist axis. Oncol Lett. 2017;14(4):4866–72.CrossRef
24.
go back to reference Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93.CrossRef Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93.CrossRef
25.
go back to reference Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96.CrossRef Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96.CrossRef
26.
go back to reference Venkateswaran N, Conacci-Sorrell M. MYC leads the way. Small GTPases. 2017:1–9. Venkateswaran N, Conacci-Sorrell M. MYC leads the way. Small GTPases. 2017:1–9.
27.
go back to reference Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, Zanucco E, Castro I, Potapenko T. MYC is a metastasis gene for non-small-cell lung cancer. PLoS One. 2009;4(6):e6029.CrossRef Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, Zanucco E, Castro I, Potapenko T. MYC is a metastasis gene for non-small-cell lung cancer. PLoS One. 2009;4(6):e6029.CrossRef
28.
go back to reference Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer discovery. 2014;4(3):318–33.CrossRef Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer discovery. 2014;4(3):318–33.CrossRef
29.
go back to reference Cowling VH, D'Cruz CM, Chodosh LA, Cole MD. C-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol. 2007;27(14):5135–46.CrossRef Cowling VH, D'Cruz CM, Chodosh LA, Cole MD. C-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol. 2007;27(14):5135–46.CrossRef
30.
go back to reference Cowling VH, Cole MD. E-cadherin repression contributes to c-Myc-induced epithelial cell transformation. Oncogene. 2007;26(24):3582–6.CrossRef Cowling VH, Cole MD. E-cadherin repression contributes to c-Myc-induced epithelial cell transformation. Oncogene. 2007;26(24):3582–6.CrossRef
Metadata
Title
The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells
Authors
Kun Pang
Zhiguo Zhang
Lin Hao
Zhenduo Shi
Bo Chen
Guanghui Zang
Yang Dong
Rui Li
Ying Liu
Jie Wang
Jianjun Zhang
Longjun Cai
Xiaoxiao Han
Conghui Han
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Metastasis
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5423-9

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine